Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Lihao Zhao†, Xiaona Cai‡, Didi Chen¹, Xuxue Ye¹, Mengdan Gao¹, Lihuai Lu¹, Huafang Su¹, Meng Su¹, Meng Hou¹ and Congying Xie*¹

Abstract

Background: The development of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has dramatically improved the prognosis of patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The purpose of this study is to investigate the clinical outcome with or without EGFR-TKI resistance before WBRT and the sequence between EGFR-TKIs and whole brain radiotherapy (WBRT) of EGFR-mutant NSCLC patients who developed multiple brain metastases (BMs).

Patients and methods: Three hundred forty-four EGFR-mutant NSCLC patients with multiple BMs were reviewed. Enrolled patients were divided into TKI-naïve group and TKI-resistant group. The intracranial progression-free survival (PFS) and overall survival (OS) were analyzed via the Kaplan-Meier method.

Results: For patients with multiple BMs treated by WBRT, the median intracranial PFS and OS were longer in the TKI-naïve group than those in the TKI-resistant group, but there were no statistically significant between two groups (Intracranial PFS: 7.7 vs. 5.4 months, p = 0.052; OS: 11.2 vs. 9.2 months, p = 0.106). For patients with Lung-molGPA 0–2, no significant differences in median intracranial PFS (6.2 vs. 5.2 months, p = 0.123) and OS (7.8 vs. 6.7 months, p = 0.514) between TKI-naïve and TKI-resistant groups. For patients with Lung-molGPA 2.5–4, intracranial PFS: 12.8 vs. 10.1 months; OS: 23.3 vs. 15.3 months.

Conclusions: Our study found that there were no difference in intracranial PFS and OS in all patients between the two groups of TKI-naïve and TKI-resistant. But for patients in subgroup of Lung-molGPA 2.5–4, there were a better intracranial PFS and OS in TKI-naïve group.

Keywords: Non-small-cell lung cancer, EGFR-TKI resistance, EGFR TKI-naïve, The treatment sequence, Whole brain radiotherapy.
developed to improve the typically dismal outcome associated with NSCLC, especially small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for its capability of crossing the BBB. In particular, the third generation of EGFR-TKI (Tagrisso) has been shown to have a good ability to control BM for patient with EGFR-mutant NSCLC [9, 10]. In the era of targeted therapy, the development of EGFR-TKIs has dramatically improved the prognosis of patients with EGFR-mutant NSCLC. These agents improve response rates (RR), prolonged progression-free survival (PFS), and overall survival (OS). However, the majority of patients who initially respond to TKI therapy will finally develop resistance to TKIs, limiting patient benefit and posing a challenge to oncologists [11]. Furthermore, the initial failure site for acquired resistance to TKIs is usually in the CNS [12]. The management of brain metastases persists as an important issue. Radiotherapy is considered as an effective therapy for brain metastases, which has yielded response rates of 50 to 75% for intracranial lesions, especially for those developed acquired resistance to TKIs [13, 14].

At present, whether acquired resistance to EGFR-TKI affects the efficacy of RT in NSCLC patients remains controversial. Currently, some scholars believe that targeted therapy synchronous WBRT may reduce the OS of patients with NSCLC with multiple BMs accompanied by EGFR mutations. Therefore, sequential therapy may be a better treatment option. However, there is still a controversy over whether to receive TKI therapy after radiotherapy or TKI therapy before radiotherapy. To clarify the influence of acquired EGFR-TKI resistance on the efficacy of radiotherapy in the treatment of NSCLC patients with multiple BMs, and how to choose the treatment sequence between the two approaches, we assessed the clinical outcomes of WBRT in the treatment of EGFR-mutant brain metastatic NSCLC patients with or without EGFR-TKI resistance.

Patients and methods

Patients

Clinical data of NSCLC patients with multiple BMs harboring EGFR mutation at the authors’ hospital from January 2008 to March 2018 were retrospectively reviewed. The eligibility criteria for this study was set as following: patients were diagnosed with NSCLC and confirmed multiple BMs by magnetic resonance imaging (MRI); patients had at least four BMs and headaches, accompanied by nausea, vomiting or visual disorder, or dizziness, tinnitus, deafness and other symptoms; patients had at least four measurable BMs according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; the EGFR mutations include exons 18 to 21, deletion on exon 19 and point mutation on exon 21; patients had no serious dysfunction of major organs (e.g. heart failure or uremia); patients had adequate function of hematologic (absolute neutrophil ≥1.5*10^9/L or platelet count ≥100*10^9/L); patients treated by WBRT for a prescription of 3 Gy *10 fractions; The exclusion criteria was set as following: patients had mixed small cell carcinoma or small cell carcinoma histologically; Patients had less than four measurable BMs lesion according to the RECIST 1.1; patients were lost to follow-up or died within 1 month after starting the treatment; patients received prior radiotherapy or targeted drugs for BM or temozolomide (TMZ); patients received concurrent radiochemotherapy; patients received radiosurgery (SRS) or surgery for BM. This study was approved by the Institutional Review Board and performed at the 1st Affiliated Hospital of Wenzhou Medical University.

The parameters of the Lung-mol GPA

The prognostic groupings of the denocarcinoma Lung-molGPA was a predictor of NSCLC patient with multiple BMs. Including the following five factors: Age, KPS, Extracranial Metastases, Number of BM, Gene status. The parameters of the Lung-molGPA were detailed in Table 1. Scores can be divided into 0–4, and lower scores that means the prognosis would be worse.

Study design

Eligible patients were divided into two groups: TKI-naïve group and TKI-resistant group. In TKI-naïve group, patients were accepted initial TKI treatment and no TKI-resistant were found before WBRT. In TKI-resistant group, patients harboring EGFR mutation, and experienced disease progression after initial benefit from TKIs or with newly-diagnosed brain metastases during TKIs treatment and/or salvage chemotherapy. Patients with different Lung Cancer Using Molecular Markers Graded Prognostic Assessment (Lung-molGPA) were further divided into two subgroups of Lung-molGPA 0–2 (with Lung-molGPA value from 0 to 2) and Lung-molGPA 2.5–4 (with Lung-molGPA value from 2.5–4).

Table 1. Lung-molGPA for NSCLC with BM Scoring Chart

| Prognostic Factor | Lung-molGPA |
|-------------------|-------------|
|                   | 0 | 0.5 | 1 |
| Age, y ≥70        | <70 | <70 | 90–100 |
| KPS < 70          | 70–80 | Absent |
| Extracranial Metastases Present | Absent |
| Number of BM > 4  | 1–4 | NA  |
| Gene status EGFR neg/unk and ALK neg/unk NA | EGFR pos or ALK pos |

Abbreviations: NSCLC Non-small-cell lung cancer, BM brain metastasis, Lung-molGPA Lung Cancer Molecular Markers Graded Prognostic Assessment, KPS Karnofsky Performance Status, NA not applicable, neg/unk negative or unknown, pos positive
WBRT was planned by two lateral parallel-opposite conformal beams with a prescription of 30 Gy at 10 fractions for a 6-MV photon beam on an Elekta Synergy® linac (Elekta Ltd., Crawley, UK). To minimize the side effects of WBRT, we used side-to-side radiation and intensity modulated radiation therapy (IMRT). Beyond that, with the development of radiotherapy technology, some patients used new radiotherapy technology which penetrating field to protect the hippocampal gyrus. (It can form a lower dose distribution in the hippocampus to achieve the purpose of protecting the hippocampus, and can effectively protect the hippocampus without reducing the dose of intracranial lesions.)

All patients were evaluated weekly during WBRT. They were followed up every 3 months for 1–3 years after the end of radiotherapy and every 6 months thereafter until death or the deadline of our study. Evaluation included a complete history review, neurologic examination, blood counts, and biochemistry profile. During follow-up evaluation including physical examination, neurologic examination, a complete blood count measurement, liver function test, and chest computed tomography (CT) scan was done monthly. Brain CT with and without contrast, abdominal CT, or bone scan, as well as MRI if necessary, were performed when there were relevant symptoms in patients.

Statistical analyses
Pearson chi-square or Fisher’s exact tests (when there were fewer than 5 expected counts in the contingency table) were used to compare the baseline characteristics of parents between TKI-naïve and TKI-resistant groups. Tumor response was assessed according to the RECIST 1.1. OS was defined as the interval from the date of initial diagnosis of brain metastasis to the date of death resulted. Intracranial PFS was defined as interval between the WBRT initiation and the date of confirming CNS progression or death from CNS progression, if death occurred within 60 days of the last CNS assessment date. If the patient’s complete follow up data was impossible to obtain or the disease did not progress, patients’ status was assumed as the last known survival and/or contact date. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0.

Intracranial PFS and OS were analyzed using the Kaplan-Meier method. Differences between two groups were compared by the log-rank test. The Cox proportional hazards model was used for univariate and multivariate analyses to identify the independent prognostic factors for PFS and OS. Statistical analyses were carried out with SPSS 22.0 software. Tests were two sided. $P$-value < 0.05 was considered statistically significant, and robust estimates of the standard error were used in all regression analyses.

Results
EGFR mutations analyses
Patients’ specimens for genetic test were obtained from primary tumor or metastatic sites through either diagnostic or surgical procedures. All samples were paraffin-embedded material. Tumor cells were isolated using micro dissection to ensure their presence in the specimens for DNA sequencing. EGFR gene was amplified by polymerase chain reaction and somatic mutations was detected using direct sequencing. The TKI drugs used by the patients were the first and second generation TKI drugs. Osimertinib was not included in this study because most patients were enrolled early.

Patient characteristics
Among total 478 NSCLC patients with multiple BMs harboring EGFR mutations in hospital during January 2008 to March 2018, 344 patients were enrolled in this study. Thirty-one patients who were lost to follow-up, 14 patients who received EGFR TKIs and 18 patients who received TMZ before WBRT, and 42 patients without WBRT were excluded. In addition, 21 patients who received second time EGFR-TKIs or pemetrexed, 8 patients had operations or SRS to treat brain metastases were also excluded. Of the 344 enrolled patients, the number of patients in Lung-molGPA 0–2 group and Lung-molGPA 2.5–4 group was 199 (57.8%) and 145 (42.2%), respectively. The percentage of patients with Lung-molGPA 0–2 group and Lung-molGPA 2.5–4 group for TKI-naïve and TKI-resistance were 71.4, 28.6 and 48.8%, 55.2%, respectively.

Patients in Lung-molGPA 0–2 group and Lung-molGPA 2.5–4 group between the TKI-naïve and TKI-resistant groups were well balanced with regard to gender, smoking, age, histology type, KPS, number of BM, extra-cranial metastases, primary disease control (Table 2).

Outcomes stratified by groups
The median intracranial PFS and OS for TKI-naïve group of all enrolled NSCLC patients were 7.7 months (95% CI, 6.6–8.7 months) and 11.2 months (95% CI, 7.7–14.6 months). As for TKI-resistant group, the median intracranial PFS and OS were 5.4 months (95% CI, 4.0–6.7 months) and 9.2 months (95% CI, 6.1–12.3 months), respectively. The PFS and OS of all enrolled patients are presented in Fig. 1. The TKI-naïve group had a longer median intracranial PFS (7.7 vs. 5.4 months, $p = 0.052$) and OS (11.2 vs. 9.2 months, $p = 0.106$) compared with the TKI-resistant group, but there were no statistically significant between two groups. Of the 199 patients in Lung-molGPA 0–2 group, 142 (71.4%) and 57 (28.6%)
Table 2 Clinical characteristics of non-small cell lung cancer patients with brain metastases harboring EGFR mutations

| Characteristics          | All patients | Patients with Lung-molGPA 0–2 | Patients with Lung-molGPA 2.5–4 |
|--------------------------|--------------|-------------------------------|---------------------------------|
|                          | TKI-naïve group (%) | TKI-resistant group (%) | p | TKI-naïve group (%) | TKI-resistant group (%) | p |
| All patients             | 207 (100)    | 137 (100)                     | 142 (100) | 57 (100) | 65 (100) | 80 (100) |
| Gender                   |              |                               |                               |                          |                         |
| Female                   | 72 (34.8)    | 53 (38.7)                     | 45 (31.7) | 21 (36.8) | 27 (41.5) | 32 (40.0) | 0.461 |
| Male                     | 135 (65.2)   | 84 (61.3)                     | 97 (68.3) | 36 (63.2) | 38 (58.5) | 48 (60.0) | 0.485 |
| Smoking                  |              |                               |                               |                          |                         |
| Never                    | 97 (46.9)    | 68 (49.6)                     | 60 (42.3) | 26 (45.6) | 37 (56.9) | 42 (52.5) | 0.614 |
| Current/former           | 110 (53.1)   | 69 (50.4)                     | 82 (57.7) | 31 (54.4) | 28 (43.1) | 38 (47.5) | 0.665 |
| Age                      |              |                               |                               |                          |                         |
| < 70                     | 162 (78.3)   | 112 (81.8)                    | 104 (73.2) | 43 (75.4) | 58 (89.2) | 69 (86.3) | 0.431 |
| ≥ 70                     | 45 (21.7)    | 25 (18.2)                     | 38 (26.8) | 14 (24.6) | 7 (10.8)  | 11 (13.7) | 0.485 |
| Histology                |              |                               |                               |                          |                         |
| Adenocarcinoma           | 116 (56.0)   | 90 (65.7)                     | 78 (54.9) | 34 (59.6) | 38 (58.5) | 56 (70.0) | 0.074 |
| Non-adenocarcinoma       | 91 (44.0)    | 47 (34.3)                     | 64 (45.1) | 23 (40.4) | 27 (41.5) | 24 (30.0) | 0.544 |
| KPS                      |              |                               |                               |                          |                         |
| < 70                     | 84 (40.6)    | 57 (41.6)                     | 70 (49.3) | 36 (63.2) | 14 (21.5) | 21 (26.3) | 0.074 |
| 70–100                   | 123 (59.4)   | 80 (58.4)                     | 72 (50.7) | 21 (36.8) | 51 (78.5) | 59 (73.7) | 0.654 |
| Number of BM             |              |                               |                               |                          |                         |
| 1–4                      | 124 (59.9)   | 84 (61.3)                     | 80 (56.3) | 24 (42.1) | 44 (67.7) | 60 (75.0) | 0.793 |
| > 4                      | 83 (40.1)    | 53 (38.7)                     | 62 (43.7) | 33 (57.9) | 21 (32.3) | 20 (25.0) | 0.669 |
| Extracranial metastases  |              |                               |                               |                          |                         |
| Absent                   | 81 (39.1)    | 47 (34.3)                     | 23 (16.2) | 8 (14.0)  | 58 (89.2) | 39 (48.8) | 0.069 |
| Present                  | 126 (60.9)   | 90 (65.7)                     | 119 (83.8) | 49 (86.0) | 7 (10.8)  | 41 (51.2) | 0.069 |
| Primary disease control  |              |                               |                               |                          |                         |
| No                       | 94 (45.4)    | 63 (46.0)                     | 72 (50.7) | 32 (56.1) | 22 (33.8) | 31 (38.8) | 0.917 |
| Yes                      | 113 (54.6)   | 74 (54.0)                     | 70 (49.3) | 25 (43.9) | 43 (66.2) | 49 (61.2) | 0.869 |

Abbreviations: NSCLC Non-small-cell lung cancer, BM brain metastasis, Lung-molGPA Lung Cancer Molecular Markers Graded Prognostic Assessment, TKI tyrosine kinase inhibitors, EGFR epidermal growth factor receptor, KPS Karnofsky Performance Status

Fig. 1 Intracranial Progression-free Survival (a) and Overall Survival (b) of all NSCLC developed multiple BMs patients
patients were in the TKI-naïve group and TKI-resistant arms. The intracranial PFS and OS of Lung-molGPA 0–2 group patients are presented in Fig. 2. The TKI-naïve group had no significant differences between the two groups in intracranial PFS (6.2 vs. 5.2 months, \( p = 0.123 \)) and OS (7.8 vs. 6.7 months, \( p = 0.514 \)). Of the 145 patients in Lung-molGPA 2.5–4 group, 65 (44.8%) and 80 (55.2%) patients were in the TKI-naïve group and TKI-resistant group. As shown in Fig. 3, the TKI-naïve arm had a significant longer median intracranial PFS (12.8 vs. 10.1 months, \( p = 0.014 \)) and OS (23.3 vs. 15.3 months, \( p = 0.005 \)) than the TKI-resistant group.

The outcomes above showed that patients with Lung-molGPA 2.5–4 and without EGFR-TKIs treatment before WBRT had the best intracranial PFS and OS. (12.8 months, 95% CI 10.3–15.4, and 23.3 months, 18.5–28.1, respectively).

**Multivariate analysis and toxicities**

Multivariate analysis on intracranial PFS and OS for all NSCLC patients and for patients with Lung-molGPA 0–2 and Lung-molGPA 2.5–4 groups were shown in Table 3. For patients with Lung-molGPA 2.5–4 groups, age \( (p = 0.01) \), extracranial metastases \( (p = 0.04) \) were associated with OS according to multivariate analysis.

Toxicities were reported in all NSCLC patients and for patients with Lung-molGPA 0–2 and Lung-molGPA 2.5–4 groups were the most frequent observed hematologic side effects, as showed in Table 4. The common grade III/IV toxicity were nausea \( (N = 142, 68.6\% \) and \( N = 95, 69.3\% \) and vomiting\( (N = 134, 64.7\% \) and \( N = 83, 60.6\% \). Most patients tolerated well with the side effects of EGFR-TKIs and WBRT after symptomatic treatments. Overall, all toxicities were generally brief, reversible, and manageable. They were well tolerated after symptomatic treatments.

**Discussion**

The efficacy of WBRT in the treatment of advanced NSCLC patients with multiple BMs was investigated in a total of 344 patients with or without acquired resistance to TKIs. The median OS in this study (11.2 and 9.2 months for TKI-naïve and TKI-resistant group, respectively) for patients were longer than reported median OS of 3–5 months [7, 15, 16]. The improved OS could be due to that all patients enrolled in this study were EGFR-mutant. Das AK et al. observed that NSCLC cells with EGFR-mutant had a better radiosensitivity compared with those with EGFR wild-type in vitro [17]. Similarly, Lee HL et al. reported that patients with mutant EGFR had higher response rates to brain radiotherapy than those with wild-type EGFR (80% vs. 46%, \( p = 0.037 \), and EGFR mutation status was the only predictor for treatment response \( (p = 0.032) \) [18]. In this study, subgroup analysis showed a better intracranial PFS and OS in Lung-molGPA 2.5–4 group compared with Lung-molGPA 0–2. Lung-molGPA score was also a significant prognostic predictor. Paul W. et al. indicated that the updated Lung-molGPA was associated with improved prognosis by incorporating the effect of EGFR and anaplastic lymphoma kinase (ALK) gene alterations on survival in NSCLC patients with BMs, comparison with Oncology Group Recursive Partitioning Analysis (RTOG RPA) and the original Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) [19].

In the era of targeted-therapy, the development of EGFR-TKIs has dramatically improved the prognosis of NSCLC patients with EGFR mutatation. The ability of EGFR inhibitors to enhance radiation antitumor activity has been reported as well [20–22]. In addition, studies have shown that EGFR-positive NSCLC patients had a higher radiosensitivity. Das et al. have shown that EGFR-mutant NSCLC cells are more sensitive to RT than EGFR wild-type NSCLC cells [17]. However, some studies had the opposite opinion and that suggest patients with EGFR mutations are resistant to RT. Kosaka T et al. observed that MET amplification, overexpression of hepatocyte growth factor and secondary threonine-to-
methionine mutation at codon 790 in exon 20 of the EGFR gene may be involved in radiation resistance [23]. Previous studies suggested that the first-line treatment of patients with advanced, recurrent, or metastatic NSCLC harboring an EGFR mutation is an EGFR-TKI [24]. A recent study, An N et al. point that first-line TKIs plus concurrent cranial radiotherapy is a promising therapeutic strategy that led to remarkable intracranial PFS improvement and survival benefits for EGFR-mutant NSCLC with BM [25]. However, lots of patients who initially respond to TKI therapy will finally develop resistance to TKIs [13]. Current guidelines recommend patients to continued use TKI after TKI-resistant for NSCLC patient with brain metastasis [26]. However, many studies have shown that acquired resistance to TKIs seems to be associated with worse efficacy of RT for brain metastases from EGFR-mutant NSCLC [26–29]. Magnuson WJ et al. found that acquired EGFR-TKI resistance may result in inferior intracranial PFS and OS compared with those using upfront radiotherapy for patients with EGFR-mutant NSCLC [29]. At present, there was no definite conclusion on whether TKI resistance could affect the efficacy of RT [11]. The purpose of this study is to investigate the clinical outcome with or without EGFR-TKI resistance before WBRT of EGFR-mutant NSCLC patients who developed BMs. This study demonstrated that there were no difference in intracranial PFS and OS in all patients between the two groups of TKI-naïve and TKI-resistant.

Previous studies suggested that the first-line treatment of patients with advanced, recurrent, or metastatic NSCLC harboring an EGFR mutation is an EGFR-TKI [24]. Whole brain radiotherapy (WBRT) is one of the effective control methods for multiple BMs [7]. Chen CH et al. found that the negative survival impact from the omission of WBRT in patients with EGFR-mutant NSCLC [30]. However, the sequencing between RT and TKIs remains an issue. Currently, it has been suggested that targeted therapy synchronous WBRT may reduce OS in patients with

![Figure 3](image-url) Intracranial Progression-free Survival (a) and Overall Survival (b) of NSCLC developed multiple BMs patients with Lung-molGPA 2.5–4

**Table 3** Multivariate analysis of factors affecting intracranial PFS and OS in the patients

| Factors                      | Intracranial PFS | OS       |
|------------------------------|------------------|----------|
|                              | HR 95%CI         | p        |
| All patients                 |                  |          |
| Gender                       | 1.10 0.50–2.41   | 0.82     |
| Smoking                      | 1.12 0.53–2.38   | 0.77     |
| Age                          | 0.99 0.65–1.52   | 0.97     |
| Histology                    | 0.82 0.54–1.23   | 0.33     |
| KPS                          | 0.90 0.58–1.40   | 0.63     |
| Number of BM                 | 0.89 0.56–1.41   | 0.61     |
| Extracranial metastases      | 0.96 0.53–1.74   | 0.89     |
| Primary disease control      | 0.10 0.93–2.16   | 0.10     |
| Patients with Lung-molGPA 0–2|                  |          |
| Gender                       | 1.04 0.52–2.09   | 0.91     |
| Smoking                      | 0.82 0.40–1.68   | 0.59     |
| Age                          | 0.85 0.52–2.09   | 0.57     |
| Histology                    | 0.91 0.52–1.56   | 0.72     |
| KPS                          | 0.61 0.32–1.15   | 0.13     |
| Number of BM                 | 0.79 0.47–1.33   | 0.38     |
| Extracranial metastases      | 0.64 0.37–1.11   | 0.11     |
| Primary disease control      | 1.39 0.83–2.32   | 0.21     |
| Patients with Lung-molGPA 2.5–4|                  |          |
| Gender                       | 1.11 0.66–1.85   | 0.70     |
| Smoking                      | 1.07 0.65–1.75   | 0.80     |
| Age                          | 1.07 0.77–1.48   | 0.70     |
| Histology                    | 0.79 0.58–1.09   | 0.15     |
| KPS                          | 1.02 0.74–1.39   | 0.93     |
| Number of BM                 | 0.97 0.71–1.34   | 0.86     |
| Extracranial metastases      | 1.19 0.87–1.64   | 0.28     |
| Primary disease control      | 1.37 0.10–1.89   | 0.05     |

Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, KPS Karnofsky Performance Status, BM brain metastasis, Lung-molGPA, Lung Cancer Molecular Markers Graded Prognostic Assessment
NSCLC who are diagnosed with multiple BMs accompanied by EGFR mutations. Therefore, sequential therapy may be a better treatment option. However, there is still a controversy over whether TKI therapy should be followed by radiotherapy first or TKI therapy first [27]. Our study demonstrated that patients with EGFR-TKIs resistance had a worse intracranial PFS and OS in Lung-molGPA 2.5–4 group (p = 0.005), compared with those without EGFR-TKIs resistance, but there were no significant differences in Lung-molGPA 0–2 group. Magnuson WJ et al. reached a similar conclusion. Patients were grouped according to the GPA, they found that patients with acquired EGFR TKI-resistance have a poor OS (78.9 vs. 19.5 months, p < 0.01) than TKI-naïve patients in GPA 2.5–4 group [29]. Li C et al. came to the same opinion. They think that the use of upfront WBRT for EGFR-mutated lung adenocarcinoma patients with multiple BM can improve ORR and OS [31]. Our data showed that the use of RT to TKI-naïve NSCLC result in better intracranial PFS and OS for patients with Lung-molGPA 2.5–4, TKI-naïve may be a beneficial prognostic factor. Based on the above researchs, we propose for patients with Lung-molGPA 2.5–4 that upfront WBRT followed by EGFR-TKI therapy would be a better treatment strategy in the treatment for EGFR-mutant NSCLC with symptomatic multiple BMs.

Osimertinib was not included in the study, mainly because it was enrolled earlier since 2008. At present, some studies have shown that osimertinib has radiotherapy sensitization effect. Wang N et al. [32] observed that osimertinib has therapeutic potential as a radiation-sensitizer in lung cancer cells harboring the EGFR T790M mutation. This is also a new direction of our research.

There are some limitations in this study: first, this study was designed retrospectively from a single-institution, which may experienced inherent bias, second, the number of patients enrolled in this study may be not sufficient. Factors that may impact the outcomes could not be fully evaluated. The number of patients enrolled in this study may not be sufficient enough and the follow-up period may be not long enough. External validation using other large database to further evaluate the prognostic effect of radiotherapy in the treatment of TKI-resistant NSCLC patients with multiple BMs would be of great value in clinical practice.

EGFR-TKI was the first-line treatment of patients with advanced, recurrent, or metastatic NSCLC harboring an EGFR mutation. At present, there was no definite conclusion on whether TKI resistance could affect the efficacy of RT.

Conclusions
Our study found that there were no difference in intracranial PFS and OS in all patients between the two groups of TKI-naïve and TKI-resistant. But for patients in subgroup of Lung-molGPA 2.5–4, there were a better intracranial PFS and OS in TKI-naïve group. However, the treatment sequence of the two treatment methods is still controversial, more large randomized clinical trials are needed for further verification.

Abbreviations
ALK: Anaplastic lymphoma kinase; BBB: Brain blood barrier; BM: Brain metastasis; CNS: Central nervous system; CT: Computed tomography; DS-GPA: Diagnosis-Specific Graded Prognostic Assessment; EGFR: Epidermal growth factor receptor; IMRT: Intensity modulated radiation therapy; KPS: Karnofsky Performance Status; Lung-molGPA: Lung Cancer Molecular Markers Graded Prognostic Assessment; MRI: Magnetic resonance imaging; NA: Not applicable; NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; neg/unk: Negative or unknown; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PFS: Progression-free survival; pos: Positive; RECIST: Response Evaluation Criteria in Solid Tumors; RTOG RPA: Oncology Group Recursive Partitioning Analysis; SRS: Radiosurgery; TKI: Tyrosine kinase inhibitors; TMZ: Temozolomide; WBRT: Whole-brain radiotherapy

Acknowledgements
None.

Authors’ contributions
DC and XY acquired and analyzed the data, XC and LZ drafted the manuscript. MG made contributions to follow up the patients. All authors read and approved the final manuscript.

Table 4 Toxicity profile for all patients

| Side effects         | TKI-naïve (N = 207) | TKI-resistant (N = 137) |
|----------------------|---------------------|------------------------|
|                      | All grades, N. (%)  | Grade III/IV, N. (%)   |
|                      |                     |                        |
| Fatigue              | 117 (56.5)          | 19 (9.1)               |
| Anorexia             | 84 (40.5)           | 18 (8.7)               |
| Diarrhea             | 23 (11.1)           | 4 (0.2)                |
| Nausea               | 142 (68.6)          | 38 (18.4)              |
| Vomiting             | 134 (64.7)          | 15 (7.2)               |
| Headache             | 105 (50.7)          | 14 (6.8)               |
| Anemia               | 113 (54.6)          | 5 (2.4)                |
| Neutropenia          | 95 (45.9)           | 17 (8.2)               |
| Thrombocytopenia     | 88 (42.5)           | 6 (2.9)                |

Abbreviations: TKI tyrosine kinase inhibitors
Funding
The study was funded by Science and technology cooperation project of Wenzhou science and technology bureau. (grant number 2018H0004).

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Radiation and Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, No.2 Fuxue Lane, Wenzhou 325000, Zhejiang, China. 2Department of Ultrasonography, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.

Received: 7 October 2019 Accepted: 23 December 2019

Published online: 31 December 2019

References
1. Chen W, Zhang S, Zou X. Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi. 2010;13(5):1488–93.
2. Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: lessons learned and future perspectives. Mol Asp Med. 2015;45:67–73.
3. Lukas RW, Wainwright DA, Laterra J. Updates from the Neuro-oncology section of the 2015 American neurological association annual meeting. Future Oncol. 2016;12(2):143–7.
4. Venur VA, Ahiwaiwa MS. Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015;4(2):18.
5. Bilous M, Sirdjebi C, Boyer A, Tomasinii P, Paulyoudat C, et al. Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer. Sci Rep. 2019;9(1):13018.
6. Huang Q, Quyan X. Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions. Cancer Epidemiol. 2013;37(5):703–7.
7. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–304.
8. Chen K, Yu X, Zhang F, Xu Y, Zhang P, et al. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases. Lung Cancer. 2018;125:8–13.
9. Porta R, Sánchez-Torres JM, Paz-Ares L, Massuti B, Reguat N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624–31.
10. Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015;6(10):8366–76.
11. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357–60.
12. Lee YY, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small-cell lung cancer. Cancer. 2011;103(3):1336–43.
13. Wang C, Lu X, Lyu Z, Bi N, Wang L. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis. Lung Cancer. 2018;122:94–5.
14. Young K. Palliation of brain and spinal cord metastases in Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1974–85.
15. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.
16. Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran W Jr, Robins H, et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 011B). Int J Radiat Oncol Biol Phys. 2008;71(1):79–86.
17. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, et al. Nonsmall cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 2016;66:9601–8.
18. Lee Hl, Chung TS, Ting LL, Tsai JT, Chen SW, Chou JF, et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol. 2012;7:181.
19. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdawala A, et al. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2017;3(6):827–31.
20. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2001;62:4300–6.
21. Chinmayan P, Huang S, Vallabhaneni G, Armstrong E, Vasamblury S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–35.
22. Milas M, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701–5.
23. Kosaka T, Yamaki E, Mogi A, Kusano H. Mechanisms of resistance to EGFR TKs and development of a new generation of drugs in non-small cell lung cancer. J Biomed Biotechnol. 2011;2011:162514.
24. Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5(9):707–16.
25. An N, Wang H, Li J, Zhai X, Jing W, et al. Therapeutic effect of first-line EGFR-TKIs combined with concurrent cranial radiotherapy on NSCLC patients with EGFR activating mutation and brain metastases: a retrospective study. Oncol Targets Ther. 2019;12:8331–8.
26. Yu HA, Sima CS, Huang J, Solomon SB, Rimmner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51.
27. Javvadi P, Makino H, Das AK, Lin YF, Chen DJ, Chen BP, et al. Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance. Mol Cancer Res. 2012;10(10):1359–68.
28. La Fleur L, Johansson AC, Roberg K. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One. 2012;7(9):e44071.
29. Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of delaying radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung Cancer who develop brain metastases. Int J Radiat Oncol Biol Phys. 2016;95(2):673–9.
30. Chen CH, Lee HH, Chuang HY, Hung JY, Huang MY, et al. Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers (Basel). 2019;11(8).
31. Li C, Guo J, Zhao L, Hu F, Nie W, et al. Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma. Cancer Manag Res. 2019;11:3433–43.
32. Wang N, Wang L, Meng X, Wang J, Zhu L, Liu C, et al. Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. Oncol Rep. 2019;41(4):77–86.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.